IPSC vs. CCCC, TNYA, TIL, SXTC, DERM, IMRX, NVCT, ACTU, CRBU, and TVGN
Should you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include C4 Therapeutics (CCCC), Tenaya Therapeutics (TNYA), Instil Bio (TIL), China SXT Pharmaceuticals (SXTC), Journey Medical (DERM), Immuneering (IMRX), Nuvectis Pharma (NVCT), Actuate Therapeutics (ACTU), Caribou Biosciences (CRBU), and Tevogen Bio (TVGN). These companies are all part of the "pharmaceutical products" industry.
Century Therapeutics vs. Its Competitors
C4 Therapeutics (NASDAQ:CCCC) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.
In the previous week, C4 Therapeutics had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 2 mentions for C4 Therapeutics and 0 mentions for Century Therapeutics. C4 Therapeutics' average media sentiment score of 1.88 equaled Century Therapeutics'average media sentiment score.
C4 Therapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 212.50%. Century Therapeutics has a consensus target price of $3.75, suggesting a potential upside of 700.94%. Given Century Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Century Therapeutics is more favorable than C4 Therapeutics.
C4 Therapeutics has a beta of 2.98, meaning that its stock price is 198% more volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500.
78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 8.7% of C4 Therapeutics shares are owned by insiders. Comparatively, 5.0% of Century Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
C4 Therapeutics has higher revenue and earnings than Century Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.
Century Therapeutics has a net margin of -19.10% compared to C4 Therapeutics' net margin of -325.88%. Century Therapeutics' return on equity of -11.53% beat C4 Therapeutics' return on equity.
Summary
Century Therapeutics beats C4 Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Century Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Century Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:IPSC) was last updated on 9/3/2025 by MarketBeat.com Staff
Free IPSC Stock Alerts